As­traZeneca adds a ma­jor PhI­II win for Farx­i­ga, set­ting up an­oth­er bat­tle­front with Big Phar­ma ri­vals

Over the past eight years, As­traZeneca has dili­gent­ly groomed Farx­i­ga, its SGLT2 in­hibitor, from just a treat­ment for type 2 di­a­betes to a drug that can al­so tack­le chron­ic kid­ney dis­ease and heart fail­ure across a swath of pa­tients.

And now, the phar­ma gi­ant says it has the da­ta to un­lock an­oth­er large mar­ket ex­pan­sion in the car­dio­vas­cu­lar space — one that once again puts it head-to-head against Eli Lil­ly and Boehringer In­gel­heim’s Jar­diance and No­var­tis’ En­tresto.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER